EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial

Andre Zimerman iD, Ana Laura F Kunzler iD, Brittany N Weber iD, Xinhui Ran iD, Sabina A Murphy iD, Huei Wang, Narimon Honarpour, Anthony C Keech iD, Peter S Sever iD, Marc S Sabatine iD, Robert P Giugliano iD

Circulation · 20.05.2025 · 151 (20) · 1467-1476

DOI: 10.1161/circulationaha.124.072756 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Circulation, erschienen am 20.05.2025. Verfasst von Andre Zimerman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Moinhos de Vento, Moinhos de Vento College of Health Sciences, Porto Alegre, Brazil (A.Z., A.L.F.K.). Hauptthemen laut MEDLINE: Anticholesteremic Agents, Atherosclerosis, Autoimmune Diseases, Cholesterol, LDL. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab lowered low-density lipoprotein cholesterol levels, but not hsCRP (high-sensitivity C-reactive protein) levels, and reduced the risk of cardiovascular events. METHODS: FOURIER was a randomized trial of evolocumab versus placebo in 27 564 patients with stable atherosclerosis who were taking statins. This analysis focused on the effect of evolocumab in patients with or without an AIID, defined as any autoimmune or chronic inflammatory condition. The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, unstable angina, or coronary revascularization. RESULTS: At baseline, 889 patients (3.2%) had an AIID, most commonly rheumatoid arthritis (33.7%) or psoriasis (15.6%). Median (interquartile range) low-density lipoprotein cholesterol levels were 90.0 mg/dL (79.5–105.5) and 91.5 mg/dL (79.5–108.5) in patients with or without an AIID, respectively ( P =0.025), and the placebo-adjusted percent reduction with evolocumab was consistent (60.2% versus 59.0%; P =0.57). Baseline hsCRP was higher in patients with an AIID (median 2.1 versus 1.7 mg/L; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anticholesteremic AgentsAtherosclerosisAutoimmune DiseasesCholesterol, LDLInflammationAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedDouble-Blind MethodPCSK9 InhibitorsProprotein Convertase 9Treatment Outcome

Stichwörter der Autor:innen

PCSK9 inhibitorsautoimmunitycholesterol, LDLinflammationlipids

Substanzen

Antibodies, Monoclonal, HumanizedAnticholesteremic AgentsCholesterol, LDLevolocumabPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Autor:innen und Institutionen

  • Hospital Moinhos de Vento, Moinhos de Vento College of Health Sciences, Porto Alegre, Brazil (A.Z., A.L.F.K.).
  • Division of Cardiovascular Medicine (B.N.W.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • TIMI Study Group (X.R., S.A.M., M.S.S., R.P.G.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Biostatistics (H.W.), Amgen, Thousand Oaks, CA.
  • Global Development (N.H.), Amgen, Thousand Oaks, CA.
  • Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia (A.C.K.).

ORCID-Profile: Andre Zimerman, Ana Laura F Kunzler, Brittany N Weber, Xinhui Ran, Sabina A Murphy, Anthony C Keech, Peter S Sever, Marc S Sabatine, Robert P Giugliano

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Zimerman, A., Kunzler, A. L. F., Weber, B. N., Ran, X., Murphy, S. A., Wang, H., Honarpour, N., Keech, A. C., Sever, P. S., Sabatine, M. S., & Giugliano, R. P. (2025). Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation, 151(20), 1467-1476. https://doi.org/10.1161/circulationaha.124.072756

Vancouver

Zimerman A, Kunzler ALF, Weber BN, Ran X, Murphy SA, Wang H, et al. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation. 2025;151(20):1467-1476. doi:10.1161/circulationaha.124.072756

BibTeX
@article{Zimerman2025,
  author = {Zimerman, Andre and Kunzler, Ana Laura F and Weber, Brittany N and Ran, Xinhui and Murphy, Sabina A and Wang, Huei and Honarpour, Narimon and Keech, Anthony C and Sever, Peter S and Sabatine, Marc S and Giugliano, Robert P},
  title = {Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial},
  journal = {Circulation},
  year = {2025},
  volume = {151},
  number = {20},
  pages = {1467--1476},
  doi = {10.1161/circulationaha.124.072756}
}
Kostenlos starten →